# VaxCell Biotherapeutics Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vaxcell-biotherapeutics-co

- Industry: Biotechnology
- Headquarters: South Korea
- Website: www.vaxcell-bio.com
- Total disclosed funding: $14M
- Latest round: Series B (Jun 1, 2018)
- Investors on record: 8

## About

Established in 2010 and based in South Korea, VaxCell Biotherapeutics Co., Ltd. operates as a biotech company that focuses on patient-specific total solution anti-cancer immunotherapy R&D. In 2020, the company was listed on the KOSDAQ.

The company's business can be categorized into the Vax-NK Platform, Vax-DC Platform, Vax-CARs Platform, and Vaxleukin-15. The company has developed immune cell therapy using natural killer cells and dendritic cells and is conducting phase 2 clinical trials.

## Funding rounds

- Series B, Jun 1, 2018, $11M — AJU IB Investment, LB Investment, Seoul Investment Partners, HB Investment, Samho Green Investment
- Series A, Dec 30, 2015, $2.5M — Hyundai Venture Investment, Yuanta Investment, NH Investment & Securities

## Investors

- Hyundai Venture Investment (https://capitalatlas.ai/funds/hyundai-venture-investment) — Series A
- Yuanta Investment (https://capitalatlas.ai/funds/yuanta-investment) — Series A
- NH Investment & Securities (https://capitalatlas.ai/funds/nh-investment-securities) — Series A
- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Series B
- LB Investment (https://capitalatlas.ai/funds/lb-investment) — Series B
- Seoul Investment Partners (https://capitalatlas.ai/funds/seoul-investment-partners) — Series B
- HB Investment (https://capitalatlas.ai/funds/hb-investment) — Series B
- Samho Green Investment (https://capitalatlas.ai/funds/samho-green-investment) — Series B